Ryvu Therapeutics zooKrakow-based oncology specialist Ryvu Therapeutics zoo today announced a strategic reorganisation that will extend Ryvu’s cash runway to H2/2026 to focus on accelerating three ongoing RVU120 clinical programmes, and early pipeline small molecule and ADC assets to key data inflection points.
Tag Archive for: BioNTech
Medilink TherapeuticsGood news for BioNTech SE: The safety study of the ADC BNT326/YL202 developed by MediLink Therapeutics, which was suspended by the FDA in mid-June, will continue.
BioNtech SE has reported preliminary Phase I/II results with BNT211-01 (NEO-PTC-01) and CarVAC at ESMO conference in Madrid
BioNTech has entered the ADC field with an exclusive license and collaboration agreement with China’s DualityBio Ltd for two antibody-drug conjugate (ADC) assets.
BioNTech SE will pay £562m in cash to acquire its former partner InstaDeep Ltd. to expand its capabilities in AI-based drug discovery.
Renewed focus on cancer: COVID-19 vaccine company BioNTech SE (Nasdaq: BNTX) and Ryvu Therapeutics S.A., located in Krakow (Warsaw Stock Exchange: RVU), a Polish clinical-stage cancer therapeutics development company, announced that the companies have entered into a research collaboration for several multi-target immunotherapy programmes, as well as an exclusive licensing agreement for Ryvu’s STING agonist portfolio as stand-alone small molecules.